Myocardial Infarction Market Size was USD 21,477 Million in 2021

The Myocardial Infarction Market Size shall grow during the forecast period (2022-2032) owing to the launch of upcoming therapies, the high prevalence of Myocardial Infarction, advances in pharmacological treatment, personalized treatment approach, advances in models of a Myocardial Infarction, and others during the forecast period (2022-2032).

Myocardial Infarction market report provides current treatment practices, Myocardial Infarction emerging drugs, and Myocardial Infarction market share of the individual therapies, current and forecasted 7MM Myocardial Infarction market size from 2019 to 2032. The report also covers current Myocardial Infarction treatment practice/algorithm and Myocardial Infarction unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Myocardial Infarction Market Report

• The total diagnosed prevalent cases of Myocardial Infarction in the 7MM comprised of approximately 15 million cases in 2021 and are projected to increase during the forecasted period.

• The total diagnosed prevalent cases of Myocardial Infarction in the United States were around 8 million cases in 2021.

• The leading Myocardial Infarction Companies include AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others.

• Promising Myocardial Infarction Pipeline Therapies include FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC, and others.

To explore more information of the latest breakthroughs of Myocardial Infarction Treatment Landscape, click here for Myocardial Infarction Market Size @ https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Myocardial Infarction Treatment Landscape

• In November 2022, Amgen presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions and simultaneously published in the New England Journal of Medicine.

• As per the Q32022 investor presentation of AstraZeneca data, readouts from the Phase III (DAPA-MI) trial of FARXIGA/FORXIGA is anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023.

• In June 2021, Idorsia announced the initiation of the Phase III registration study "SOS-AMI" to evaluate the efficacy and safety of self-administered SC selatogrel in suspected AMI.

• In September 2020, the FDA granted Fast Track designation for the development of JARDIANCE to prevent hospitalization for heart failure and reduce the risk of mortality in patients with and without diabetes who have had an acute MI.

• In July 2020, AstraZeneca was granted Fast Track designation in the US for the development of FARXIGA to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an AMI or heart attack.

Myocardial Infarction Overview

Myocardial infarction (MI) refers to ischemic necrosis of myocardial tissue. The most common underlying cause is coronary artery disease. Type 1 MI occurs when an unstable plaque ruptures, leading to the occlusion of a coronary artery. Type 2 MI occurs when there is a mismatch between oxygen supply and demand (e.g., systemic hypotension, vasospasm). MI manifests clinically with acute coronary syndrome (ACS), a potentially lethal condition.

Myocardial Infarction Epidemiology Segmentation in the 7MM

• Myocardial Infarction Diagnosed Prevalent Cases

• Myocardial Infarction Gender-specific Prevalence

• Myocardial Infarction Type-specific Prevalence

To know more information of the Myocardial Infarction Epidemiology Segmentation of the report, click here for Myocardial Infarction Epidemiology Insights @ https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Myocardial Infarction Marketed Drugs

• INSPRA (eplerenone): Pfizer
INSPRA (eplerenone) is a steroid nucleus-based mineralocorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone. Eplerenone is thought to be a more selective blocker at the mineralocorticoid receptor since there is evidence that some of the effects result from a blockade of cortisol stimulation of the MR-receptor. It is indicated for improving survival of stable patients with LV systolic dysfunction (LVEF =40%) and CHF after acute myocardial infarction.

• PLAVIX (clopidogrel bisulfate): Sanofi-Aventis/Bristol-Myers Squibb
Sanofi-Aventis's PLAVIX is a P2Y12 platelet inhibitor that reduces the risk of death and cardiovascular complications in patients with symptomatic atherosclerotic disease in the setting of percutaneous coronary intervention (PCI) and in patients with unstable angina or non-STEMI. It is indicated for the acute coronary syndrome (ACS), recent MI, recent stroke, or established peripheral arterial disease.

• BRILINTA (ticagrelor): AstraZeneca
BRILINTA (ticagrelor) is an oral, reversible, direct-acting P2Y12 receptor antagonist that works by inhibiting platelet activation. BRILINTA, together with aspirin, has been shown to significantly reduce the risk of MACE, defined as myocardial infarction (MI, heart attack), stroke, or CV death, in patients with ACS or a history of MI. BRILINTA, co-administered with aspirin, is indicated to prevent atherothrombotic events in adult patients with ACS or for patients with a history of MI and a high risk of developing an atherothrombotic event. It is marketed as BRILIQUE in the EU.

• PRALUENT (alirocumab): Regeneron/Sanofi
PRALUENT is a PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody developed by Sanofi. In the US, PRALUENT is approved to reduce the risk of heart attack, stroke, and unstable angina. PRALUENT is also approved as an adjunct to diet, alone or in combination with other lipid lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce LDL-C

Myocardial Infarction Emerging Drugs Profile

• FARXIGA/FORXIGA (dapagliflozin): AstraZeneca
Dapagliflozin is a first-in-class, oral, once-daily SGLT2 inhibitor. Research has shown FARXIGA's efficacy in preventing and delaying cardiorenal disease while protecting the organs - important findings given the underlying links between the heart, kidneys, and pancreas. FARXIGA is currently being tested in the DAPA-MI Phase III trial, a first-of-its-kind, registry-based randomized controlled trial in patients without type 2 diabetes following an acute MI or heart attack. The DAPA-MI trial is conducted in collaboration with Uppsala Clinical Research Center (UCR) and Myocardial Ischaemia National Audit Project (MINAP) in the UK. In July 202, AstraZeneca was granted FTD in the US for the development of FARXIGA to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an AMI or heart attack.

• JARDIANCE (empagliflozin): Boehringer Ingelheim and Eli Lilly and Company
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for glucose re-absorption in the kidney. It is marketed under the brand name JARDIANCE and is the first type 2 diabetes medicine to include cardiovascular death risk reduction data on the label in several countries. Empagliflozin lowers blood glucose levels by preventing glucose re-absorption in the kidneys and increasing the amount of glucose excreted in the urine. It has a relatively long duration of action requiring only once-daily dosing. As its mechanism of action is contingent on the renal excretion of glucose, empagliflozin may be held in cases of acute kidney injury and/or discontinued in patients who develop chronic renal disease In September 2020, the FDA granted FTD for the development of JARDIANCE to prevent hospitalization for heart failure and reduce the risk of mortality in patients with and without diabetes who have had an acute MI.

• Olpasiran: Amgen
Olpasiran (formerly AMG 890) is a small interfering RNA designed to lower the body's production of apolipoprotein(a), a key component of Lp(a) that has been associated with an increased risk of cardiovascular events. In November 2022, the company presented end-of-treatment data from its Phase II OCEAN (a)-DOSE study of olpasiran in adults with elevated lipoprotein(a) [Lp(a)] levels (>150 nmol/L) and a history of atherosclerotic cardiovascular disease (ASCVD) during the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2022, and simultaneously published in the New England Journal of Medicine. Moreover, the FDA granted Fast Track designation (FTD) for olpasiran to treat atherosclerotic cardiovascular disease.

Myocardial Infarction Market Outlook
Myocardial Infarction (MI) commonly known as a heart attack occurs when blood flow declines or stops in a part of the heart, triggering damage to the heart muscle. Acute myocardial infarction (AMI), a common manifestation of CVD in the elderly, carries an increased risk of mortality, morbidity, and excess costs. Currently, there are multiple effective management options following myocardial infarction, and guidelines recommend lifelong pharmaceutical prevention with beta-blockers, ACE inhibitors or angiotensin II receptor blockers, acetylsalicylic acid, and statins if not contraindicated.

Browse More Related Reports of the Myocardial Infarction Market Research Reports, click here for Myocardial Infarction Market Forecast @ https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Myocardial Infarction Market Report

• Coverage- 7MM

• Myocardial Infarction Companies- AstraZeneca, Boehringer Ingelheim and Eli Lilly and Company, Amgen, Novartis, Idorsia Pharmaceuticals, Faraday Pharmaceuticals, CSL Behring, Immediate Therapeutics, Mitsubishi Chemical Group, Kancera, Bayer, Recardio, Mesoblast, and others.

• Myocardial Infarction Pipeline Therapies- FARXIGA/FORXIGA (dapagliflozin), JARDIANCE (empagliflozin), Olpasiran (AMG860), Pelacarsen (TQJ230), Selatogrel, FDY-5301, CSL112, IMT-358, CL2020, MEDI6570, KAND567, Asundexian, Dutogliptin, MPC-25-IC, and others.

• Myocardial Infarction Market Dynamics: Myocardial Infarction Market Drivers and Barriers

• Myocardial Infarction Market Access and Reimbursement, Unmet Needs, Future Perspectives

Read the Full Research Report of the Myocardial Infarction Market Forecast Report, click here for Myocardial Infarction Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Myocardial Infarction Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Myocardial Infarction Market Overview at a Glance
7. Disease Background and Overview
8. Treatment and Management
9. Guidelines and Recommendations for MI
10. Epidemiology and Patient Population of Myocardial infarction (MI) in the 7MM
11. Patient Journey
12. Myocardial Infarction Marketed Therapies
13. Myocardial Infarction Emerging Therapies
14. Myocardial infarction (MI): 7MM Analysis
15. Myocardial Infarction Unmet Needs
16. Myocardial Infarction SWOT Analysis
17. KOL Views
18. Myocardial Infarction Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Consult with our Business Expert @ Myocardial Infarction Market Landscape- https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.